Abstract：
On January 18, 2024, the US Centers for Disease Control and Prevention issued their most recent guidelines for over-the-counter drugs for coronavirus disease 2019 (COVID-19). Specifically, the organization stated that \"Most people with COVID-19 have mild illness and can recover at home. You can treat symptoms with over-the-counter medicines, such as acetaminophen (Tylenol) or ibuprofen (Motrin, Advil), to help you feel better.\" In this review we consider the contributions of different types of evidence and conclude that healthcare providers should make individual clinical judgments for each of their patients in the selection of over-the-counter drugs to treat symptoms of COVID-19. This judgment should be based on the entire benefit to risk profile of the patient. It is our belief that the individual healthcare provider knows far more about each of his or her patients than anyone, including expert members of guideline committees. Their astute and judicious individual clinical decision-making for each individual patient based on all these considerations has the potential to do far more good than harm.
摘要：
2024年1月18日，美国（US）疾病控制和预防中心（CDC）发布了最新的COVID-19非处方药指南。疾病预防控制中心表示，“大多数COVID-19患者患有轻度疾病，可以在家康复。你可以用非处方药治疗症状，例如对乙酰氨基酚（泰诺）或布洛芬（Motrin，Advil),帮助你感觉更好。“在这篇评论中，我们考虑了不同类型证据的贡献，并得出结论，医疗保健提供者在选择治疗COVID-19症状的非处方药时，应该为他或她的每个患者做出单独的临床判断。此判断应基于患者的整体获益与风险特征。我们相信，个人医疗保健提供者比任何人都更了解他或她的每个患者，包括指导委员会的专家成员。基于所有这些考虑，他们为每位患者做出的精明而明智的个人临床决策可能会带来远胜于伤害的好处。
